Biosimilar Notice Rule Isn't Absolute, Apotex Tells Fed. Circ.
Apotex urged a Federal Circuit panel to reverse a lower court's finding that biosimilar makers must always give 180-day advance notice of sales to brand-name rivals, arguing in a dispute over a...To view the full article, register now.
Already a subscriber? Click here to view full article